​

Cullinan Therapeutics (CGEM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CGEM Stock Forecast

Cullinan Therapeutics (CGEM) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $32.67, with a high of $38.00 and a low of $26.00. This represents a 164.32% increase from the last price of $12.36.

$10 $16 $22 $28 $34 $40 High: $38 Avg: $32.67 Low: $26 Last Closed Price: $12.36

CGEM Stock Rating

Cullinan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CGEM Price Target Upside V Benchmarks

TypeNameUpside
StockCullinan Therapeutics164.32%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts333
Avg Price Target$32.67$32.67$32.67
Last Closing Price$12.36$12.36$12.36
Upside/Downside164.32%164.32%164.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2519---10
Nov, 2528---10
Oct, 2528---10
Sep, 2528---10
Aug, 2518---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2025Robert DriscollWedbush$34.00$12.18179.15%175.08%
Nov 24, 2025Julian HarrisonBTIG$38.00$11.90219.33%207.44%
Nov 20, 2025New Street$26.00$8.92191.48%110.36%
Oct 24, 2024David DaiUBS$30.00$15.6192.18%142.72%
Aug 08, 2024Jeffrey HungMorgan Stanley$38.00$16.38131.99%207.44%
May 16, 2024Edward WhiteH.C. Wainwright$28.00$26.724.79%126.54%
Apr 17, 2024Kaveri PohlmanBTIG$30.00$17.3273.21%142.72%
Apr 16, 2024Edward WhiteH.C. Wainwright$29.00$17.6364.49%134.63%
Feb 03, 2023Morgan Stanley$19.00$11.9159.53%53.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 09, 2025WedbushOutperformOutperformhold
Nov 24, 2025BTIGBuyBuyhold
Jan 29, 2025H.C. WainwrightBuyBuyhold
Oct 29, 2024BTIGBuyBuyhold
Oct 24, 2024UBSBuyinitialise
Oct 17, 2024H.C. WainwrightBuyBuyhold
Sep 18, 2024BTIGBuyBuyhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.17$-1.47$-3.69-----
Avg Forecast$-2.04$-1.28$-4.09$-3.04$-3.10$-3.00$-2.33$-2.87
High Forecast$-1.42$-0.89$-4.05$-2.95$-2.51$-2.42$-0.05$-1.60
Low Forecast$-2.67$-1.67$-4.13$-3.33$-4.09$-4.65$-4.12$-4.14
Surprise %-42.65%14.84%-9.78%-----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$18.94M------
Avg Forecast$4.50M$18.91M-$1.67M$10.65M$33.02M$56.13M$58.02M
High Forecast$5.56M$23.38M-$2.24M$14.28M$33.16M$56.64M$77.82M
Low Forecast$3.44M$14.46M-$1.10M$7.02M$32.89M$55.62M$38.24M
Surprise %-0.15%------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-50.85M$-65.04M$-153.16M-----
Avg Forecast$-84.76M$-53.08M$-169.76M$-130.49M$-137.20M$-146.98M$-86.74M$-119.11M
High Forecast$-58.80M$-36.82M$-168.11M$-122.60M$-104.43M$-100.70M$-2.28M$-66.31M
Low Forecast$-110.75M$-69.35M$-171.42M$-138.38M$-169.96M$-193.27M$-171.21M$-171.96M
Surprise %-40.01%22.53%-9.78%-----

CGEM Forecast FAQ

Is Cullinan Therapeutics stock a buy?

Cullinan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cullinan Therapeutics is a favorable investment for most analysts.

What is Cullinan Therapeutics's price target?

Cullinan Therapeutics's price target, set by 8 Wall Street analysts, averages $32.67 over the next 12 months. The price target range spans from $26 at the low end to $38 at the high end, suggesting a potential 164.32% change from the previous closing price of $12.36.

How does Cullinan Therapeutics stock forecast compare to its benchmarks?

Cullinan Therapeutics's stock forecast shows a 164.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for Cullinan Therapeutics over the past three months?

  • December 2025: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cullinan Therapeutics’s EPS forecast?

Cullinan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.04, marking a -17.62% decrease from the reported $-3.69 in 2023. Estimates for the following years are $-3.1 in 2025, $-3 in 2026, $-2.33 in 2027, and $-2.87 in 2028.

What is Cullinan Therapeutics’s revenue forecast?

Cullinan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $1.67M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $10.65M, followed by $33.02M for 2026, $56.13M for 2027, and $58.02M for 2028.

What is Cullinan Therapeutics’s net income forecast?

Cullinan Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-130M, representing a -14.80% decrease from the reported $-153M in 2023. Projections indicate $-137M in 2025, $-147M in 2026, $-86.744M in 2027, and $-119M in 2028.